Leszek Nosek - Profil | 人才画像

基本信息

浏览量：22

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 148 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Safety and performance of an advanced hybrid closed-loop algorithm with ultra rapid lispro and lispro

R. K. Pollom,L. Nosek, H. Veir Coester,E. Zijlstra,A. Ghosh,A. Haidar, R. E. Jones,J. K. Leohr, S. E. Gleissner,E. Dassau, M. Katz

DIABETOLOGIAno. SUPPL 1 (2023): S394-S394

引用0浏览0引用

105-LB: Safety and Performance of an Advanced Hybrid Closed-Loop (AHCL) Algorithm with Ultra-rapid Lispro (urli) and Lispro

Robyn K. Pollom,Leszek Nosek,Hans Veit Coester,Eric Zijlstra, Aritra Ghosh,Ahmad Haidar,Richard Jones,Jennifer Leohr, Stephanie E. Gleissner,Eyal Dassau,Michelle Katz

DIABETES (2023)

引用0浏览0引用

New Clamp-PID Algorithm for Automated Glucose Clamps Improves Clamp Quality

Carsten Benesch,Mareike Kuhlenkotter,Leszek Nosek,Tim Heise

Journal of diabetes science and technology（2021）

引用3浏览0WOS引用

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (urli) Versus Humalog® (lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study

Leohr Jennifer,Dellva Mary Anne,Coutant David E.,LaBell Elizabeth,Heise Tim,Andersen Grit,Zijlstra Eric,Hermanski Lidia,Nosek Leszek,Linnebjerg Helle

Clinical pharmacokinetics（2020）

引用25浏览0WOS引用

A Single‐dose Euglycaemic Clamp Study in Two Cohorts to Compare the Exposure of SAR341402 (insulin Aspart) Mix 70/30 with US‐ and European‐approved Versions of Insulin Aspart Mix 70/30 and SAR341402 Rapid‐acting Solution in Subjects with Type 1 Diabetes

Christoph Kapitza,Leszek Nosek,Wolfgang Schmider,Lenore Teichert,Bhaswati Mukherjee,Irene Nowotny

Diabetes Obesity and Metabolism（2020）

引用4浏览0WOS引用

Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes

Christoph Kapitza,Leszek Nosek,Wolfgang Schmider,Lenore Teichert,Irene Nowotny

Diabetes technology & therapeutics（2020）

引用14浏览0WOS引用

130-LB: Comparative PK and PD of the Rapid-Acting Insulin Aspart Product SAR341402, NovoLog, and NovoRapid in Subjects with T1D

Christoph Kapitza,Leszek Nosek,Anne Lehmann,Wolfgang Schmider,Baerbel Rotthaeuser,Irene K. Nowotny

Diabetes（2019）

引用2浏览0引用

Ultra Rapid Lispro (URLi) accelerates insulin lispro absorption and insulin action vs lispro in patients with type 2 diabetes

J. Leohr,M. Dellva,D. Coutant,E. LaBell,S. Reddy,S. Bowerman,T. Heise,G. Andersen,E. Zijlstra,L. Hermanski,L. Nosek,H. Linnebjerg

DIABETOLOGIA（2019）

引用0浏览0引用

Un Effet Hypoglycémiant Précoce Plus Élevé Et Constant De L’insuline FasterAspart Vs Insuline Aspart

Bruno Guerci,Leszek Nosek, Hannel L. Haahr,Tim Heise,Ulrike Hovelmann,Lars Erichsen,Eric Zijlstra,Kristine Stender-Petersen,Meriem Kessouri

Diabetes & Metabolismno. 2 (2017): A115-A115

引用0浏览0引用

Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects with Type 1 Diabetes

Eric Zijlstra,Marek Demissie,Tina Graungaard,Tim Heise,Leszek Nosek,Bruce Bode

Journal of Diabetes Science and Technology（2017）

引用45浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn